{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:29Z","timestamp":1786997849316,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2025.110986","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:07:32Z","timestamp":1769155652000},"page":"110986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: Moving from risk factors to micrometastatic disease in the perioperative setting"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-2959","authenticated-orcid":false,"given":"Sergio","family":"Bracarda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Mammone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sirgiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.110986_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101763","article-title":"Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials","volume":"37","author":"Nawaf","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0002","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci"},{"key":"10.1016\/j.urolonc.2025.110986_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"Van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0004","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.3390\/jcm13072057","article-title":"Plasma-derived cell-free DNA as a biomarker for early detection, prognostication, and personalized treatment of urothelial carcinoma","volume":"13","author":"Bhalla","year":"2024","journal-title":"JCM"},{"key":"10.1016\/j.urolonc.2025.110986_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0006","article-title":"Emerging biomarkers in urothelial carcinoma: challenges and opportunities","volume":"25","author":"Andreatos","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.urolonc.2025.110986_bib0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40336-018-0269-8","article-title":"The role of PET\/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis","volume":"6","author":"Cervino","year":"2018","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.urolonc.2025.110986_bib0009","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/1097-0142(197906)43:6<2532::AID-CNCR2820430654>3.0.CO;2-B","article-title":"Bladder carcinoma as a systemic disease","volume":"43","author":"Prout","year":"1979","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.110986_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtr\u00f6der","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0011","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0012","doi-asserted-by":"crossref","first-page":"45619","DOI":"10.18632\/oncotarget.17312","article-title":"Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient","volume":"8","author":"Prado","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2025.110986_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0014","article-title":"Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.urolonc.2025.110986_bib0015","series-title":"Tumor liquid biopsies","first-page":"181","article-title":"Enrichment and analysis of ctDNA","volume":"215","author":"Gilson","year":"2020"},{"key":"10.1016\/j.urolonc.2025.110986_bib0016","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.euf.2022.04.017","article-title":"Circulating tumour DNA is a strong predictor of outcomes in patients treated with systemic therapy for urothelial carcinoma","volume":"8","author":"Laukhtina","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2025.110986_bib0017","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma \u2014 upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41585-023-00783-6","article-title":"Author correction: circulating and urinary tumour DNA in urothelial carcinoma \u2014 upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0019","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.3390\/cancers14205019","article-title":"Predicting recurrence of non-muscle-invasive bladder cancer: current techniques and future trends","volume":"14","author":"Shalata","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.110986_bib0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2025.110986_bib0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1515\/medgen-2023-2065","article-title":"The changing face of circulating tumor DNA (ctDNA) profiling: factors that shape the landscape of methodologies, technologies, and commercialization","volume":"35","author":"Bronkhorst","year":"2023","journal-title":"Medizinische Genetik"},{"key":"10.1016\/j.urolonc.2025.110986_bib0022","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.110986_bib0023","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/oncolo\/oyae198","article-title":"High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions","volume":"29","author":"Patel","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2025.110986_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1221718","article-title":"Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling\u2013informed personalized monitoring assay","volume":"13","author":"Powles","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.euo.2024.11.008","article-title":"Circulating tumor DNA: a new research frontier in urological oncology from localized to metastatic disease","volume":"8","author":"Garofoli","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0031","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0032","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant Atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0034","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant Atezolizumab in muscle-invasive bladder cancer","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.110986_bib0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/path.6166","article-title":"Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS -03 trial","volume":"261","author":"Zang","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0036","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","article-title":"Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial","volume":"30","author":"Powles","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2025.110986_bib0028","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fonc.2020.00755","article-title":"Clinical significance of hotspot mutation analysis of urinary cell-free DNA in urothelial bladder cancer","volume":"10","author":"Hayashi","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2023.09.017","article-title":"Novel use of circulating tumor DNA to identify muscle-invasive and non\u2013organ-confined upper tract urothelial carcinoma","volume":"85","author":"Huelster","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0026","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.110986_bib0027","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3892\/or.2023.8543","article-title":"Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease (Review)","volume":"49","author":"Chen","year":"2023","journal-title":"Oncol Rep"},{"key":"10.1016\/j.urolonc.2025.110986_bib0030","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3390\/cancers15204987","article-title":"Upper tract urothelial carcinoma (UTUC) diagnosis and risk stratification: a comprehensive review","volume":"15","author":"Bitaraf","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.110986_bib0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2025.110986_bib0037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103109","article-title":"ctDNA as a cancer biomarker: a broad overview","volume":"155","author":"Pessoa","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107458","article-title":"Circulating tumor DNA as an early cancer detection tool","volume":"207","author":"Campos-Carrillo","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.urolonc.2025.110986_bib0040","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","article-title":"Practical recommendations for using ctDNA in clinical decision making","volume":"619","author":"Cohen","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2025.110986_bib0041","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.21037\/tau.2019.12.21","article-title":"Risk stratification for upper tract urinary carcinoma","volume":"9","author":"Benamran","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2025.110986_bib0042","unstructured":"EAU guidelines on upper urinary tract urothelial carcinoma. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Upper-Urinary-Tract-Urothelial-Carcinoma-2024.pdf 2024, Accessed June 5, 2025."},{"key":"10.1016\/j.urolonc.2025.110986_bib0043","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.110986_bib0044","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41551-021-00837-3","article-title":"Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics","volume":"6","author":"Song","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.urolonc.2025.110986_bib0045","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","article-title":"Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer","volume":"7","author":"Tolmeijer","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.110986_bib0046","article-title":"Exploring circulating tumor DNA (CtDNA) and its role in early detection of cancer: a systematic review","volume":"15","author":"Bittla","year":"2023","journal-title":"Cureus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500523X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500523X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:51:12Z","timestamp":1784548272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392500523X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S107814392500523X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110986","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: Moving from risk factors to micrometastatic disease in the perioperative setting","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110986","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110986"}}